|
US5994392A
(en)
|
1988-02-26 |
1999-11-30 |
Neuromedica, Inc. |
Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
|
|
US5268164A
(en)
*
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
|
US5545719A
(en)
*
|
1990-05-01 |
1996-08-13 |
Neuromedica, Inc. |
Nerve growth peptides
|
|
US5439884A
(en)
*
|
1992-07-27 |
1995-08-08 |
Oregon Regional Primate Research Center |
Method of controlling fertilization using bombesin or its agonist
|
|
KR100291620B1
(ko)
*
|
1992-09-29 |
2001-10-24 |
추후제출 |
부갑상선호르몬의활성단편의폐를통한전달방법
|
|
US5434137A
(en)
*
|
1993-05-10 |
1995-07-18 |
Black; Keith L. |
Method for selective opening of abnormal brain tissue capillaries
|
|
EP0740548B1
(en)
*
|
1994-02-28 |
2002-12-04 |
Nanopharm AG |
Drug targeting system, method for preparing same and its use
|
|
US20030113273A1
(en)
*
|
1996-06-17 |
2003-06-19 |
Patton John S. |
Methods and compositions for pulmonary delivery of insulin
|
|
EP0748213B1
(en)
|
1994-03-07 |
2004-04-14 |
Nektar Therapeutics |
Methods and compositions for pulmonary delivery of insulin
|
|
US5962477A
(en)
*
|
1994-04-12 |
1999-10-05 |
Adolor Corporation |
Screening methods for cytokine inhibitors
|
|
US6190691B1
(en)
|
1994-04-12 |
2001-02-20 |
Adolor Corporation |
Methods for treating inflammatory conditions
|
|
GB2288732B
(en)
*
|
1994-04-13 |
1998-04-29 |
Quadrant Holdings Cambridge |
Pharmaceutical compositions
|
|
US5585355A
(en)
*
|
1994-04-22 |
1996-12-17 |
Alkermes, Inc. |
Method for increasing blood-ocular barrier permeability with permeabilizer peptides
|
|
KR100384353B1
(ko)
*
|
1994-05-18 |
2003-10-04 |
네크타르 테라퓨틱스 |
인터페론의건조분말제형을제조하기위한방법및조성물
|
|
US6290991B1
(en)
*
|
1994-12-02 |
2001-09-18 |
Quandrant Holdings Cambridge Limited |
Solid dose delivery vehicle and methods of making same
|
|
US5849761A
(en)
*
|
1995-09-12 |
1998-12-15 |
Regents Of The University Of California |
Peripherally active anti-hyperalgesic opiates
|
|
US6573282B1
(en)
|
1995-09-12 |
2003-06-03 |
Adolor Corporation |
Peripherally active anti-hyperalgesic opiates
|
|
WO1997041856A1
(en)
*
|
1996-05-08 |
1997-11-13 |
Massachusetts Institute Of Technology |
ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO)
|
|
US6576636B2
(en)
|
1996-05-22 |
2003-06-10 |
Protarga, Inc. |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
|
|
US5795909A
(en)
*
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
|
US5752515A
(en)
*
|
1996-08-21 |
1998-05-19 |
Brigham & Women's Hospital |
Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier
|
|
US6942963B1
(en)
|
1997-01-10 |
2005-09-13 |
Massachusetts Institute Of Technology |
Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides
|
|
US6172043B1
(en)
|
1997-01-10 |
2001-01-09 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's disease caused by β amyloid peptides
|
|
US20030035778A1
(en)
*
|
1997-07-14 |
2003-02-20 |
Robert Platz |
Methods and compositions for the dry powder formulation of interferon
|
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
|
US6309623B1
(en)
*
|
1997-09-29 |
2001-10-30 |
Inhale Therapeutic Systems, Inc. |
Stabilized preparations for use in metered dose inhalers
|
|
US6225444B1
(en)
|
1998-02-10 |
2001-05-01 |
Protarga, Inc. |
Neuroprotective peptides and uses thereof
|
|
CA2356460A1
(en)
*
|
1998-12-23 |
2000-06-29 |
Cytoscan Sciences L.L.C. |
Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
|
|
US6630120B1
(en)
|
1999-03-08 |
2003-10-07 |
Alkermes, Inc. |
Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors
|
|
US7235583B1
(en)
|
1999-03-09 |
2007-06-26 |
Luitpold Pharmaceuticals, Inc., |
Fatty acid-anticancer conjugates and uses thereof
|
|
US6774119B1
(en)
*
|
1999-04-26 |
2004-08-10 |
Cedars-Sinai Medical Center |
Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
|
|
AU782298B2
(en)
|
1999-10-04 |
2005-07-14 |
Nektar Therapeutics |
Polymer stabilized neuropeptides
|
|
US20050153940A1
(en)
*
|
2000-01-26 |
2005-07-14 |
Cedars-Sinai Medical Center |
Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
|
|
JP2003523965A
(ja)
*
|
2000-01-26 |
2003-08-12 |
シーダース シナイ メディカル センター |
異常な脳領域および／または悪性腫瘍に薬剤をデリバリーするためにカリウムチャンネルアゴニストを使用する方法
|
|
US7018979B1
(en)
|
2000-01-26 |
2006-03-28 |
Cedars-Sinai Medical Center |
Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
|
|
US7235397B1
(en)
*
|
2000-04-14 |
2007-06-26 |
Gensys, Inc. |
Methods and compositions for culturing spirochete and treating spirochetal diseases
|
|
US8404217B2
(en)
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
|
US7442388B2
(en)
|
2000-05-10 |
2008-10-28 |
Weers Jeffry G |
Phospholipid-based powders for drug delivery
|
|
US8251986B2
(en)
|
2000-08-17 |
2012-08-28 |
Angiodynamics, Inc. |
Method of destroying tissue cells by eletroporation
|
|
US7067550B2
(en)
*
|
2000-11-03 |
2006-06-27 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's Disease
|
|
WO2002035987A2
(en)
*
|
2000-11-03 |
2002-05-10 |
Massachusetts Institute Of Technology |
METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES
|
|
JP4634694B2
(ja)
*
|
2001-03-23 |
2011-02-16 |
ルイトポルド・ファーマシューティカルズ・インコーポレーテッド |
脂肪アルコール薬物複合体
|
|
US8552054B2
(en)
*
|
2001-03-23 |
2013-10-08 |
Luitpold Pharmaceuticals, Inc. |
Fatty amine drug conjugates
|
|
US7211561B2
(en)
*
|
2001-10-12 |
2007-05-01 |
Cedars-Sinai Medical Center |
Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
|
|
WO2003053411A1
(en)
|
2001-12-19 |
2003-07-03 |
Nektar Therapeutics |
Pulmonary delivery of aminoglycosides
|
|
WO2004069857A2
(en)
*
|
2003-02-06 |
2004-08-19 |
Uutech Limited |
“peptides, compositions and uses thereof”
|
|
US7485706B2
(en)
*
|
2003-07-30 |
2009-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Neurodegenerative protein aggregation inhibition methods and compounds
|
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
|
WO2005089496A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
WO2005089504A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
WO2005089502A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
US20050272068A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
UCH-L1 expression and cancer therapy
|
|
WO2005089515A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
ZA200704140B
(en)
*
|
2004-11-16 |
2008-08-27 |
Limerick Neurosciences Inc |
Methods and compositions for treating pain
|
|
US20070087977A1
(en)
*
|
2004-11-16 |
2007-04-19 |
Wendye Robbins |
Methods and compositions for treating pain
|
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
|
WO2006091542A2
(en)
*
|
2005-02-22 |
2006-08-31 |
Cedars-Sinai Medical Center |
Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
|
|
EP1957093B1
(en)
|
2005-08-29 |
2017-04-12 |
SHASHOUA, Victor E. |
Neuroprotective and neurorestorative methods and compositions
|
|
EP3309170B1
(en)
|
2005-12-15 |
2019-05-22 |
Genentech, Inc. |
Polyubiquitin antibodies
|
|
CA2634598A1
(en)
|
2005-12-23 |
2007-07-05 |
Link Medicine Corporation |
Treatment of synucleinopathies
|
|
US20070259820A1
(en)
*
|
2006-05-03 |
2007-11-08 |
The Regents Of The University Of Michigan |
Methods and reagents for activating heat shock protein 70
|
|
EP2016097A2
(en)
|
2006-05-04 |
2009-01-21 |
Genentech, Inc. |
Methods and compositions relating to zpa polypeptides
|
|
ME01075B
(me)
|
2006-07-14 |
2012-10-20 |
Ac Immune Sa |
Antitijela
|
|
RU2498999C2
(ru)
|
2006-07-14 |
2013-11-20 |
Ац Иммуне Са |
Гуманизированное антитело к амилоиду бета
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
TWI557136B
(zh)
|
2007-06-12 |
2016-11-11 |
Ａｃ免疫公司 |
特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途
|
|
TWI516500B
(zh)
|
2007-06-12 |
2016-01-11 |
Ａｃ免疫公司 |
抗β類澱粉蛋白單株抗體
|
|
ES2609918T3
(es)
|
2007-10-05 |
2017-04-25 |
Genentech, Inc. |
Uso de anticuerpo anti-amiloide beta en enfermedades oculares
|
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗－ｖｅｇｆ抗體
|
|
WO2009151683A2
(en)
*
|
2008-03-12 |
2009-12-17 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
|
US8992517B2
(en)
|
2008-04-29 |
2015-03-31 |
Virginia Tech Intellectual Properties Inc. |
Irreversible electroporation to treat aberrant cell masses
|
|
US10238447B2
(en)
|
2008-04-29 |
2019-03-26 |
Virginia Tech Intellectual Properties, Inc. |
System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
|
|
US11272979B2
(en)
|
2008-04-29 |
2022-03-15 |
Virginia Tech Intellectual Properties, Inc. |
System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
|
|
US10448989B2
(en)
|
2009-04-09 |
2019-10-22 |
Virginia Tech Intellectual Properties, Inc. |
High-frequency electroporation for cancer therapy
|
|
US10702326B2
(en)
|
2011-07-15 |
2020-07-07 |
Virginia Tech Intellectual Properties, Inc. |
Device and method for electroporation based treatment of stenosis of a tubular body part
|
|
US10245098B2
(en)
|
2008-04-29 |
2019-04-02 |
Virginia Tech Intellectual Properties, Inc. |
Acute blood-brain barrier disruption using electrical energy based therapy
|
|
US9198733B2
(en)
|
2008-04-29 |
2015-12-01 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning for electroporation-based therapies
|
|
AU2009243079A1
(en)
|
2008-04-29 |
2009-11-05 |
Virginia Tech Intellectual Properties, Inc. |
Irreversible electroporation to create tissue scaffolds
|
|
US9283051B2
(en)
|
2008-04-29 |
2016-03-15 |
Virginia Tech Intellectual Properties, Inc. |
System and method for estimating a treatment volume for administering electrical-energy based therapies
|
|
US10272178B2
(en)
|
2008-04-29 |
2019-04-30 |
Virginia Tech Intellectual Properties Inc. |
Methods for blood-brain barrier disruption using electrical energy
|
|
US10117707B2
(en)
|
2008-04-29 |
2018-11-06 |
Virginia Tech Intellectual Properties, Inc. |
System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
|
|
US11254926B2
(en)
|
2008-04-29 |
2022-02-22 |
Virginia Tech Intellectual Properties, Inc. |
Devices and methods for high frequency electroporation
|
|
US9867652B2
(en)
|
2008-04-29 |
2018-01-16 |
Virginia Tech Intellectual Properties, Inc. |
Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
|
|
WO2010009271A2
(en)
|
2008-07-15 |
2010-01-21 |
Academia Sinica |
Glycan arrays on ptfe-like aluminum coated glass slides and related methods
|
|
CN102245208B
(zh)
|
2008-10-14 |
2016-03-16 |
霍夫曼-拉罗奇有限公司 |
免疫球蛋白变体及其用途
|
|
CN104689316A
(zh)
|
2008-10-22 |
2015-06-10 |
弗·哈夫曼-拉罗切有限公司 |
轴突变性的调节
|
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
|
WO2010057006A1
(en)
*
|
2008-11-13 |
2010-05-20 |
Link Medicine Corporation |
Azaquinolinone derivatives and uses thereof
|
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
|
EP2367798B1
(en)
|
2008-11-20 |
2018-02-28 |
Northwestern University |
Pyrazolone derivatives useful in the treatment of amyotrophic lateral sclerosis
|
|
US20120009182A1
(en)
|
2008-12-23 |
2012-01-12 |
Genentech, Inc. |
Immunoglobulin variants with altered binding to protein a
|
|
EP2389160B1
(en)
*
|
2009-01-23 |
2017-09-13 |
Evonik Corporation |
Continuous double emulsion process for making microparticles
|
|
US8632534B2
(en)
|
2009-04-03 |
2014-01-21 |
Angiodynamics, Inc. |
Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD)
|
|
US11638603B2
(en)
|
2009-04-09 |
2023-05-02 |
Virginia Tech Intellectual Properties, Inc. |
Selective modulation of intracellular effects of cells using pulsed electric fields
|
|
US11382681B2
(en)
|
2009-04-09 |
2022-07-12 |
Virginia Tech Intellectual Properties, Inc. |
Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
|
|
US20120046309A1
(en)
|
2009-05-05 |
2012-02-23 |
Northwestern University |
Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
|
|
US8903488B2
(en)
|
2009-05-28 |
2014-12-02 |
Angiodynamics, Inc. |
System and method for synchronizing energy delivery to the cardiac rhythm
|
|
AU2010256360A1
(en)
|
2009-06-05 |
2012-01-12 |
Astrazeneca Ab |
Aminopyrrolidinone derivatives and uses thereof
|
|
US9895189B2
(en)
|
2009-06-19 |
2018-02-20 |
Angiodynamics, Inc. |
Methods of sterilization and treating infection using irreversible electroporation
|
|
DK2473522T3
(en)
|
2009-09-02 |
2016-11-28 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
|
KR20120102642A
(ko)
|
2009-10-22 |
2012-09-18 |
제넨테크, 인크. |
축삭 변성의 조절
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
CA2783934A1
(en)
|
2009-12-11 |
2011-06-16 |
Genecode As |
Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
|
|
US8486397B2
(en)
|
2009-12-11 |
2013-07-16 |
Genentech, Inc. |
Anti-VEGF-C antibodies and methods using same
|
|
MX2012007379A
(es)
|
2009-12-23 |
2012-08-31 |
Genentech Inc |
Anticuerpos anti-bv8 y usos de los mismos.
|
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
AU2011250970B2
(en)
|
2010-05-10 |
2016-12-15 |
Sinica, Academia |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
|
MY164579A
(en)
|
2010-07-30 |
2018-01-15 |
Ac Immune Sa |
Safe and functional humanized antibodies
|
|
WO2012020124A1
(en)
|
2010-08-12 |
2012-02-16 |
Ac Immune S.A. |
Vaccine engineering
|
|
ES2588981T3
(es)
|
2010-10-05 |
2016-11-08 |
Genentech, Inc. |
Smoothened mutante y métodos de uso de la misma
|
|
SI2625198T1
(sl)
|
2010-10-07 |
2015-11-30 |
Ac Immune S.A. Epfl Innovation Park |
Protitelesa, ki prepoznavajo fosfo-tau
|
|
EP2627274B1
(en)
|
2010-10-13 |
2022-12-14 |
AngioDynamics, Inc. |
System for electrically ablating tissue of a patient
|
|
CN103189050B
(zh)
|
2010-10-26 |
2017-09-29 |
Ac免疫有限公司 |
包含通过疏水部分修饰的肽的基于脂质体的构建体
|
|
CA2815840A1
(en)
|
2010-11-10 |
2012-05-18 |
Genentech, Inc. |
Methods and compositions for neural disease immunotherapy
|
|
WO2012177997A1
(en)
|
2011-06-22 |
2012-12-27 |
The General Hospital Corporation |
Treatment of proteinopathies
|
|
US9078665B2
(en)
|
2011-09-28 |
2015-07-14 |
Angiodynamics, Inc. |
Multiple treatment zone ablation probe
|
|
RU2639537C2
(ru)
|
2011-10-07 |
2017-12-21 |
Ац Иммуне С.А. |
Фосфоспецифичные антитела, распознающие тау
|
|
WO2013056054A2
(en)
|
2011-10-14 |
2013-04-18 |
Genentech, Inc |
Peptide inhibitors of bace1
|
|
AR088827A1
(es)
|
2011-11-10 |
2014-07-10 |
Genentech Inc |
Metodos para tratar, diagnosticar, y monitorear la enfermedad de alzheimer
|
|
US9414881B2
(en)
|
2012-02-08 |
2016-08-16 |
Angiodynamics, Inc. |
System and method for increasing a target zone for electrical ablation
|
|
WO2013144113A1
(en)
|
2012-03-26 |
2013-10-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for prevention or treatment of ischemia related organ damage
|
|
WO2013151762A1
(en)
|
2012-04-05 |
2013-10-10 |
Ac Immune S.A. |
Humanized tau antibody
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
EP2852584B1
(en)
|
2012-05-22 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Substituted dipyridylamines and uses thereof
|
|
JP6038297B2
(ja)
|
2012-05-22 |
2016-12-07 |
ジェネンテック， インコーポレイテッド |
Ｎ−置換ベンズアミドおよび疼痛の処置におけるそれらの使用
|
|
JP6309519B2
(ja)
|
2012-07-06 |
2018-04-11 |
ジェネンテック， インコーポレイテッド |
Ｎ置換ベンズアミド及びその使用方法
|
|
JP6302909B2
(ja)
|
2012-08-18 |
2018-03-28 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
シアリダーゼの同定および画像化のための細胞透過性プローブ
|
|
US9547009B2
(en)
|
2012-08-21 |
2017-01-17 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
|
TW201418201A
(zh)
|
2012-09-27 |
2014-05-16 |
Hoffmann La Roche |
經取代之磺醯胺化合物
|
|
AU2013204200B2
(en)
|
2012-10-11 |
2016-10-20 |
Brandeis University |
Treatment of amyotrophic lateral sclerosis
|
|
TWI498325B
(zh)
|
2013-01-18 |
2015-09-01 |
Hoffmann La Roche |
３－取代吡唑及其用途
|
|
US9888956B2
(en)
|
2013-01-22 |
2018-02-13 |
Angiodynamics, Inc. |
Integrated pump and generator device and method of use
|
|
CN105263490B
(zh)
|
2013-03-14 |
2018-05-22 |
基因泰克公司 |
取代的三唑并吡啶及其使用方法
|
|
BR112015023262B8
(pt)
|
2013-03-15 |
2024-02-06 |
Ac Immune Sa |
Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
|
|
KR20160002850A
(ko)
|
2013-05-01 |
2016-01-08 |
에프. 호프만-라 로슈 아게 |
C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도
|
|
MA42164B1
(fr)
|
2013-05-01 |
2019-12-31 |
Hoffmann La Roche |
Composes biheteroaryle et leurs utilisations
|
|
EP3013365B1
(en)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Rm2 antigens and use thereof
|
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
|
WO2015035337A1
(en)
|
2013-09-06 |
2015-03-12 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS
|
|
NZ714555A
(en)
|
2013-09-17 |
2020-03-27 |
Obi Pharma Inc |
Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
|
|
KR20160064230A
(ko)
|
2013-10-11 |
2016-06-07 |
에프. 호프만-라 로슈 아게 |
Trpa1 조절제로서 유용한 치환된 헤테로환형 설폰아마이드 화합물
|
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
KR20160104727A
(ko)
|
2014-01-16 |
2016-09-05 |
아카데미아 시니카 |
암의 치료 및 검출을 위한 조성물 및 방법
|
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
KR20160107303A
(ko)
*
|
2014-01-17 |
2016-09-13 |
웨이크 포리스트 유니버시티 헬스 사이언시즈 |
활성 작용제 전달의 강화 방법
|
|
AU2015214264B2
(en)
|
2014-02-04 |
2018-12-20 |
Curis, Inc. |
Mutant Smoothened and methods of using the same
|
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
|
CN106715682A
(zh)
|
2014-05-12 |
2017-05-24 |
弗吉尼亚暨州立大学知识产权公司 |
使用脉冲电场选择性调节细胞的胞内影响
|
|
KR20220151036A
(ko)
|
2014-05-27 |
2022-11-11 |
아카데미아 시니카 |
항-ｃｄ20 글리코항체 및 이의 용도
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
CA2950440A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
|
TWI654202B
(zh)
|
2014-05-27 |
2019-03-21 |
中央研究院 |
增進抗體功效之通用糖型之組合物及方法
|
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
|
CN106715418A
(zh)
|
2014-07-07 |
2017-05-24 |
基因泰克公司 |
治疗化合物及其使用方法
|
|
US12114911B2
(en)
|
2014-08-28 |
2024-10-15 |
Angiodynamics, Inc. |
System and method for ablating a tissue site by electroporation with real-time pulse monitoring
|
|
KR102422375B1
(ko)
|
2014-09-08 |
2022-07-18 |
아카데미아 시니카 |
당지질을 사용한 인간 iNKT 세포 활성화
|
|
ES2848376T3
(es)
|
2014-11-19 |
2021-08-09 |
Axon Neuroscience Se |
Anticuerpos de tau humanizados en la enfermedad de Alzheimer
|
|
EP3221364B1
(en)
|
2014-11-19 |
2020-12-16 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
|
US10694972B2
(en)
|
2014-12-15 |
2020-06-30 |
Virginia Tech Intellectual Properties, Inc. |
Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
CN112430268A
(zh)
|
2015-01-24 |
2021-03-02 |
中央研究院 |
癌症标记及其使用方法
|
|
EP3789766A1
(en)
|
2015-01-24 |
2021-03-10 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
|
CN107614521B
(zh)
|
2015-01-30 |
2022-02-08 |
台湾地区“中央研究院” |
增进抗体功效的通用糖型组合物及方法
|
|
US10330683B2
(en)
|
2015-02-04 |
2019-06-25 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
JP6701225B2
(ja)
|
2015-03-09 |
2020-05-27 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
三環式ｄｌｋ阻害剤及びその使用
|
|
PE20180575A1
(es)
|
2015-05-22 |
2018-04-04 |
Genentech Inc |
Benzamidas sustituidas y metodos para utilizarlas
|
|
CN108137477A
(zh)
|
2015-08-27 |
2018-06-08 |
基因泰克公司 |
治疗化合物及其使用方法
|
|
HK1256912A1
(zh)
|
2015-09-04 |
2019-10-04 |
台湾浩鼎生技股份有限公司 |
聚糖阵列以及使用方法
|
|
EP3380466A1
(en)
|
2015-11-25 |
2018-10-03 |
Genentech, Inc. |
Substituted benzamides useful as sodium channel blockers
|
|
CA3007641C
(en)
|
2015-12-09 |
2023-10-17 |
Brandeis University |
Dbh inhibitors for treating or preventing memory loss
|
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス，インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
|
JP2019515876A
(ja)
|
2016-03-08 |
2019-06-13 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
Ｎ−グリカンおよびそのアレイのモジュール合成のための方法
|
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
US11041017B2
(en)
|
2016-03-29 |
2021-06-22 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
EP3854782A1
(en)
|
2016-03-30 |
2021-07-28 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
EP3445395A4
(en)
|
2016-04-22 |
2019-12-25 |
OBI Pharma, Inc. |
CANCER IMMUNOTHERAPY BY MEANING OR IMMUNULATING VIA ANTIGENS OF THE GLOBO SERIES
|
|
EP3487853B1
(en)
|
2016-07-20 |
2022-06-08 |
F. Hoffmann-La Roche AG |
Bicyclic proline compounds
|
|
WO2018015411A1
(en)
|
2016-07-20 |
2018-01-25 |
F. Hoffmann-La Roche Ag |
Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators
|
|
KR20190067765A
(ko)
|
2016-07-27 |
2019-06-17 |
오비아이 파머 인코퍼레이티드 |
면역원성/치료 글리칸 조성물 및 그의 용도
|
|
EP3491026A4
(en)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
|
|
WO2018029288A1
(en)
|
2016-08-12 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Sulfonyl pyridyl trp inhibitors
|
|
WO2018039274A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
|
EP3526219B1
(en)
|
2016-10-17 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Bicyclic pyridone lactams and methods of use thereof
|
|
US10905492B2
(en)
|
2016-11-17 |
2021-02-02 |
Angiodynamics, Inc. |
Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
|
|
CA3044274A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
|
EP3544979B1
(en)
|
2016-11-28 |
2021-08-04 |
F. Hoffmann-La Roche AG |
Oxadiazolones as transient receptor potential channel inhibitors
|
|
EP3548484B1
(en)
|
2016-12-02 |
2025-04-30 |
F. Hoffmann-La Roche AG |
Bicyclic amide compounds and methods of use thereof
|
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
|
JP7178357B2
(ja)
|
2017-03-07 |
2022-11-25 |
エフ．ホフマン－ラ ロシュ アーゲー |
オキサジアゾール一過性受容器電位チャネル阻害剤
|
|
EP3601273B1
(en)
|
2017-03-24 |
2021-12-01 |
Genentech, Inc. |
4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
|
|
SI3652178T1
(sl)
|
2017-07-14 |
2024-05-31 |
F. Hoffmann-La Roche Ag |
Biciklične ketonske spojine in načini njihove uporabe
|
|
EP3460057A1
(en)
|
2017-09-22 |
2019-03-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Kdac variants and uses thereof
|
|
CR20200151A
(es)
|
2017-10-11 |
2020-05-23 |
Hoffmann La Roche |
Compuestos bicíclicos y métodos de utilización de los mismos
|
|
CR20200168A
(es)
|
2017-10-31 |
2020-07-12 |
Hoffmann La Roche |
Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
|
|
CA3084073C
(en)
|
2017-11-30 |
2023-04-25 |
Hanmi Pharm. Co., Ltd. |
Salts of 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and crystalline forms thereof
|
|
US11607537B2
(en)
|
2017-12-05 |
2023-03-21 |
Virginia Tech Intellectual Properties, Inc. |
Method for treating neurological disorders, including tumors, with electroporation
|
|
EP3703820A4
(en)
|
2017-12-06 |
2020-12-09 |
Ovid Therapeutics Inc. |
USE OF MIR101 OR MIR128 IN THE TREATMENT OF EPILEPTIC DISORDERS
|
|
JP6987104B2
(ja)
*
|
2017-12-28 |
2021-12-22 |
テックフィールズ ファーマ カンパニー リミテッド |
パ−キンソン病治療用の新規高透過薬物及びその組成物
|
|
TW202000201A
(zh)
|
2018-02-20 |
2020-01-01 |
瑞士商赫孚孟拉羅股份公司 |
製備1-芳基磺醯基-吡咯啶-2-甲醯胺瞬時受體電位通道拮抗劑化合物及其結晶型式之方法
|
|
AR114263A1
(es)
|
2018-02-26 |
2020-08-12 |
Genentech Inc |
Compuestos terapéuticos y métodos para utilizarlos
|
|
US11311329B2
(en)
|
2018-03-13 |
2022-04-26 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
|
|
US11925405B2
(en)
|
2018-03-13 |
2024-03-12 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning system for immunotherapy enhancement via non-thermal ablation
|
|
US12390262B2
(en)
|
2018-03-13 |
2025-08-19 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning system for immunotherapy enhancement via non-thermal ablation
|
|
US10710994B2
(en)
|
2018-03-19 |
2020-07-14 |
Genentech, Inc. |
Oxadiazole transient receptor potential channel inhibitors
|
|
CA3095443A1
(en)
|
2018-03-28 |
2019-10-03 |
Axon Neuroscience Se |
Antibody-based methods of detecting and treating alzheimer's disease
|
|
JP2021519788A
(ja)
|
2018-03-30 |
2021-08-12 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物
|
|
CN112074519B
(zh)
|
2018-04-20 |
2024-08-02 |
豪夫迈·罗氏有限公司 |
作为rip1激酶抑制剂用于治疗例如肠易激综合征(ibs)的化合物
|
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
TWI853822B
(zh)
|
2018-06-27 |
2024-09-01 |
台灣浩鼎生技股份有限公司 |
用於糖蛋白工程的糖苷合成酶變體及其使用方法
|
|
CN112805267B
(zh)
|
2018-09-03 |
2024-03-08 |
豪夫迈·罗氏有限公司 |
用作tead调节剂的甲酰胺和磺酰胺衍生物
|
|
EP3908586B1
(en)
|
2019-01-11 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
|
|
US11950835B2
(en)
|
2019-06-28 |
2024-04-09 |
Virginia Tech Intellectual Properties, Inc. |
Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy
|
|
US12214189B2
(en)
|
2019-07-24 |
2025-02-04 |
Virginia Tech Intellectual Properties, Inc. |
Fourier analysis spectroscopy for monitoring tissue impedance changes and treatment outcome during electroporation-based-therapies
|
|
AU2020341681B2
(en)
|
2019-09-06 |
2024-02-15 |
Rigel Pharmaceuticals, Inc. |
RIP1 inhibitory compounds and methods for making and using the same
|
|
US11564930B2
(en)
|
2019-09-06 |
2023-01-31 |
Rigel Pharmaceuticals, Inc. |
RIP1 inhibitory compounds and methods for making and using the same
|
|
AU2020378407B2
(en)
|
2019-11-07 |
2024-02-01 |
Rigel Pharmaceuticals, Inc. |
Heterocyclic RIP1 inhibitory compounds
|
|
KR20220101138A
(ko)
|
2019-11-13 |
2022-07-19 |
제넨테크, 인크. |
치료적 화합물 및 사용 방법
|
|
AU2020394842A1
(en)
|
2019-12-04 |
2022-06-30 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
CN116615452A
(zh)
|
2020-08-14 |
2023-08-18 |
Ac免疫有限公司 |
人源化抗tdp-43结合分子及其用途
|
|
CR20230183A
(es)
|
2020-10-02 |
2023-06-14 |
Genentech Inc |
Proceso para la preparación de compuestos de biheteroarilo y formas cristalinas de estos
|
|
EP4229082A1
(en)
|
2020-10-16 |
2023-08-23 |
AC Immune SA |
Antibodies binding to alpha-synuclein for therapy and diagnosis
|
|
US12485279B2
(en)
|
2020-11-25 |
2025-12-02 |
Virginia Tech Intellectual Properties, Inc. |
Methods for modulating temporal infrastructure of pulsed electric fields
|
|
TW202300490A
(zh)
|
2021-03-11 |
2023-01-01 |
美商雷傑製藥公司 |
雜環rip1激酶抑制劑
|
|
WO2023028077A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
Sodium channel inhibitors and methods of designing same
|
|
WO2023028056A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
3-amino piperidyl sodium channel inhibitors
|
|
US12110276B2
(en)
|
2021-11-24 |
2024-10-08 |
Genentech, Inc. |
Pyrazolo compounds and methods of use thereof
|
|
WO2023097194A2
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
MX2024009948A
(es)
|
2022-02-16 |
2024-08-22 |
Ac Immune Sa |
Moleculas de union anti-tdp-43 humanizadas y usos de las mismas.
|
|
JP2025513799A
(ja)
|
2022-04-08 |
2025-04-30 |
エイシー イミューン ソシエテ アノニム |
抗ｔｄｐ－４３結合分子
|
|
CN120917043A
(zh)
|
2023-03-08 |
2025-11-07 |
Ac免疫有限公司 |
抗tdp-43结合分子及其用途
|